Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Photobiomodulation therapy (PBMT) regulates the production of IL-10 and IFN-Ɣ by peripheral blood mononuclear cells (PBMC) and CD4+ T cells isolated from subjects with Multiple Sclerosis (MS)

Miguel Tolentino, Chi C. Cho and Jeri-Anne Lyons
J Immunol May 1, 2019, 202 (1 Supplement) 193.16;
Miguel Tolentino
1University of Wisconsin Milwaukee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chi C. Cho
1University of Wisconsin Milwaukee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeri-Anne Lyons
1University of Wisconsin Milwaukee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Multiple sclerosis (MS) is a CD4+ Th1/Th17 mediated autoimmune disease characterized by myelin destruction, neurodegeneration and mitochondrial dysfunction. Current therapies suppress inflammation during early stages but are not effective in chronic stages characterized by oxidative damage. New therapies to slow progression, offer neuroprotection, and ameliorate the symptoms at any stage are urgently needed. Photobiomodulation therapy (PBMT) with light at 600–1100 nm is demonstrated to improve inflammatory and neurodegenerative disorders by down-regulating pro-inflammatory mediators and up-regulating anti-inflammatory mediators.

Our lab showed that PBMT with 670nm light reduced clinical severity in the C57BL/6 experimental autoimmune encephalomyelitis (EAE) model of MS by down-regulation of oxidative stress, apoptosis and pro-inflammatory cytokines, and up-regulation of anti-inflammatory cytokines. Data presented here evaluate the effect of PBMT on cytokine production by immune cells isolated from MS patients and healthy donors. PBMC and CD4+ T cells activated with Phytohaemagglutinin (PHA) or CD3/CD28 activator, respectively, received PBMT in vitro and cytokines were measured in cell culture supernatants by ELISA. Light at 670nm and 830nm increased IL-10 and reduced IFN-Ɣ produced by PBMC from MS patients. Light at 670nm, 735nm and 830nm increased IL-10, whereas 670nm and 830nm, but not 735nm, light reduced IFN-Ɣ produced by CD4+ T cells. Light at 670nm and 830nm reduced IFN-Ɣ produced by PBMC, while 830nm light increased IL-10 production by CD4+ T cells isolated from healthy donors. Our results demonstrate that PBMT differentially regulates the immune response in persons with MS and healthy donors.

  • Copyright © 2019 by The American Association of Immunologists, Inc.
Previous
Back to top

In this issue

The Journal of Immunology
Vol. 202, Issue 1 Supplement
1 May 2019
  • Table of Contents
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Photobiomodulation therapy (PBMT) regulates the production of IL-10 and IFN-Ɣ by peripheral blood mononuclear cells (PBMC) and CD4+ T cells isolated from subjects with Multiple Sclerosis (MS)
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Photobiomodulation therapy (PBMT) regulates the production of IL-10 and IFN-Ɣ by peripheral blood mononuclear cells (PBMC) and CD4+ T cells isolated from subjects with Multiple Sclerosis (MS)
Miguel Tolentino, Chi C. Cho, Jeri-Anne Lyons
The Journal of Immunology May 1, 2019, 202 (1 Supplement) 193.16;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Photobiomodulation therapy (PBMT) regulates the production of IL-10 and IFN-Ɣ by peripheral blood mononuclear cells (PBMC) and CD4+ T cells isolated from subjects with Multiple Sclerosis (MS)
Miguel Tolentino, Chi C. Cho, Jeri-Anne Lyons
The Journal of Immunology May 1, 2019, 202 (1 Supplement) 193.16;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

  • The cytoplasmic domain of CTLA-4 control autoimmunity via inducing regulatory T cells
  • IL-22 and Reg3γ overexpression affects Experimental Autoimmune Encephalomyelitis Severity
  • Alcohol consumption leads to sex-specific amelioration of disability in a mouse model of multiple sclerosis
Show more Advances in therapeutic approaches for neuroimmunologic diseases

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606